Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 1, 2007, Pages 84-87

  Willmore Payne, Carlynn ^a   Metzger, Ken ^a   Layfield, Lester J ^a,b  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; FISH; Fixatives; Formalin; Her 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIXATIVE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER TISSUE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE FIXATION;

BREAST NEOPLASMS; ENVIRONMENTAL POLLUTION; FEMALE; FIXATIVES; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; TISSUE FIXATION;

EID: 34247586753     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000209866.20581.8e     Document Type: Article

References (6)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
2. Vogel C, Cobleigh M, Tripathy D, et al. First-line non-hormonal treatment of women with Her-2 positive metastatic breast cancer with Herceptin (trastazumab, humanized anti-Her-2 antibody). Program and abstracts of the American Society of Clinical Oncology 36th Annual Meeting; May 20-23, 2000; New Orleans, Louisiana. Abstract 275.
3. Mass RD, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Program and abstracts of the American Society of Clinical Oncology 36th Annual Meeting; May 20-23, 2000; New Orleans, Louisiana. Abstract 291.
4. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast criteria direct comparison of fluorescence in-situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
5. Hammock L, Lewis M, Phillips C, et al. Strong Her-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in-situ hybridization. Hum Pathol. 2003;34:1034-1047.
6. Willmore C, Holden JA, Layfield LJ. Correlation of HER-2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. AIMM. Appl Immunohistochem Mol Morphol. 2005;13:333-341.